Comparative Pharmacology
Head-to-head clinical analysis: PEXEVA versus PROZAC WEEKLY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEXEVA versus PROZAC WEEKLY.
PEXEVA vs PROZAC WEEKLY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
90 mg orally once weekly
None Documented
None Documented
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Fluoxetine: 4-6 days after single dose, 4-6 days (extended to 7-9 days with chronic dosing due to autoinhibition of CYP2D6); norfluoxetine: 9-31 days. Steady state achieved after 2-4 weeks.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Renal excretion of metabolites (primarily fluoxetine glucuronide and norfluoxetine glucuronide) accounts for approximately 80% of elimination; fecal excretion accounts for approximately 15%.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant